omniture
logo
Search
璧辰（上海）医药科技有限公司 ABM THERAPEUTICS SHANGHAI COMPANY LIMITED
Media Room

Latest News

rss

ABM Therapeutics' ABM-1310 Granted Fast Track Designation by the FDA Following Orphan Drug Designation

SAN DIEGO and SHANGHAI, Sept. 26, 2023 /PRNewswire/ -- ABM Therapeutics is pleased to announce toda...

2023-09-27 00:00 1763

ABM Therapeutics Announces First Patient Dosed in Phase I Study of ABM-1310 in patients with BRAF V600 in Relapsed and Drug Resistant Primary Malignant Brain Tumors

SAN DIEGO, Calif. and SHANGHAI, Sept. 1, 2023 /PRNewswire/ -- ABM Therapeutics, a clinical-stage bi...

2023-09-02 00:00 3176

U.S. FDA Grants Orphan Drug Designation to ABM-1310 for the Treatment of Patients with Glioblastoma Harboring BRAF V600 Mutation

SAN DIEGO and SHANGHAI, Aug. 2, 2023 /PRNewswire/ -- ABM Therapeutics (ABM) announced today that th...

2023-08-03 00:00 1257

ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor

SAN DIEGO and SHANGHAI, May 4, 2023 /PRNewswire/ -- ABM Therapeutics, an innovative clinical-stage ...

2023-05-05 01:00 2540

ABM Therapeutics Receives IND Approval in China for BRAF Inhibitor ABM-1310

SAN DIEGO and SHANGHAI, Nov. 30, 2021 /PRNewswire/ -- ABM Therapeutics (ABM), a clinical-stage biop...

2021-11-30 13:00 1701
ABM Therapeutics Receives IND Approval in China for BRAF Inhibitor ABM-1310

ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA

SAN DIEGO, June 22, 2020 /PRNewswire/ -- ABM Therapeutics, a clinical-stage biopharmaceutical compa...

2020-06-22 23:00 4256
ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA